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Articular cartilage provides a near frictionless surface for the articulating ends of
bones. Cartilage functions to lubricate and transmit compressive forces resulting from
joint loading and impact. If damaged, whether by traumatic injury or disease, cartilage
lacks the ability for self-repair.
This study explores the production of scaffold-free cartilage and investigates the
effect of Tissue Growth Technologies’ CartiGen Bioreactor on the cartilage. Chondrocyte
and bone marrow-derived stem cell (BMSC) attachment to chitosan is also investigated in
hopes of producing a bilayered construct for osteochondral repair.
Results demonstrate that culturing of scaffold-free cartilage in the CartiGen
bioreactor resulted in an enhancement of the scaffold-free cartilage’s biomechanical and
biochemical properties and that the chitosan microspheres were able to successfully
support porcine chondrocyte and BMSC attachment. Results from both studies are
encouraging for future work involving tissue engineered cartilage.
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CHAPTER I
INTRODUCTION
Articular Cartilage
Articular cartilage, also known as hyaline cartilage, is a smooth and glossy tissue
that lines the ends of articulating bones. Cartilage possesses a high capacity to bear load
and a low coefficient of friction, promoting the smooth articulation of one bone against
another.

Articular cartilage serves as a shock absorber and functions to transmit

compressive forces resulting from joint loading and impact. Damage to cartilage can be
caused by trauma, disease, or normal wear and tear and can lead to irritation, pain, and
reduced joint mobility. Cartilage lacks a direct blood supply, and thus has a limited
capacity for self repair. If left untreated, further degradation may occur, causing damage
to the surrounding healthy cartilage. These lesions or defects in cartilage may progress
towards osteoarthritis (OA). At this time, a satisfactory and long-term solution has yet to
be identified for healing damaged cartilage. Advances in knowledge and technology
have led tissue engineering to emerge as a promising therapy for generating a functional
tissue substitute with properties similar to native tissue. In order to achieve this goal, a
basic understanding of the composition, structure, and behavior of cartilage is required.
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Figure 1.1

Sketch of the knee joint (a), side view on femoral condyle of an open joint
(b), and arthroscopic view of a healthy human knee joint (c). From [1].

Composition
Articular cartilage is composed of cells known as chondrocytes, which are
surrounded by a complex extracellular matrix (ECM). Chondrocytes only account for
about 1% of the volume of articular cartilage with the other 99% represented by ECM.
Articular cartilage consists of mostly water, which accounts for about 70-80% of the
tissue’s weight. The remaining solid fraction of the tissue is composed primarily of
collagen (10-30%) and proteoglycans

(3-10%). The organization of the collagen and

proteoglycans provides articular cartilage with its unique viscoelastic property.
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Figure 1.2

Illustration of the extracellular matrix (ECM) composition of articular
cartilage. From [1].

Chondrocytes are the highly specialized cells of articular cartilage and are
sparsely spread throughout the tissue. As a result, articular cartilage has the lowest
volumetric cellular density of any tissue in the human body [1]. Chondrocytes are
spheroidal shaped cells that exhibit no cell-to-cell contact and often reside as single,
isolated cells in small cavities known as lacunae. Chondrocytes play an essential role in
the maintenance of the tissue by synthesizing all the necessary components of the ECM.
Matrix metabolism is therefore regulated by chondrocytes, as the cells control the
secretion and degradation of ECM proteins. Although the overall metabolic activity of
cartilage is very low due to the low population of cells within the tissue, the individual
metabolic activity of chondrocytes is very high. Microscopically, chondrocytes possess a
prominent Golgi Apparatus and a large, granular endoplasmic reticulum, both of which
3

help to support the cell’s high metabolic activity. Because articular cartilage is avascular,
nutrient and oxygen transport to chondrocytes is facilitated by diffusion from the synovial
fluid into the cartilage matrix and thus is a very slow process. Chondrocytes demonstrate
the distinct ability to sense changes in the surrounding mechanical environment, and are
known to modify matrix production in response to mechanical stimuli.
Collagen is a structural protein that makes up about two-thirds of the dry weight
of articular cartilage. Collagen is composed of repeating chains of amino acids which
form into a characteristic triple helix structure. Type II collagen is the most abundant
form found in articular cartilage, although types III, VI, IX, X, XI, XII, and XIV are also
present in much smaller amounts. The tensile strength of articular cartilage is provided
by the abundance of type II collagen, but is also dependent on the amount of crosslinking of collagen and the zonal changes in fiber organization. Collagen turnover is a
very slow process, with collagen generally lasting an entire lifetime.
Proteoglycans are macromolecules composed of a core protein to which numerous
negatively charged glycosaminoglycans (GAG) subunits are attached. The two main
types of GAGs are chondroitin sulfate and keratin sulfate. Proteoglycans can exist as
monomers or can aggregate and bind to a hyaluronic acid chain via link proteins to form
large proteoglycan aggegrates.

The large size of these proteoglycan aggregates, or

aggrecans, keeps the proteoglycans restrained within the collagen network.

The

entrapment of proteoglycans, along with the negative charge of the numerous GAG side
chains, provides the compressive stiffness of articular cartilage.
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Figure 1.3

Schematic representation of the molecular organization of an aggregated
proteoglycan molecule. From (bjr.birjournals.org)

Structure
Articular cartilage is comprised of four distinct zones spanning from the articular
surface down to the subchondral bone.

The four zones are known as superficial

(or tangential), middle (or transitional), deep (or radial), and the calcified cartilage zone.
These four zones can be identified by differences in biochemical content and
organization, as well as chondrocyte number, shape, and metabolic activity.
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Figure 1.4

Structure of articular cartilage. (A) Schematic diagram of the cellular
organization throughout the zone of articular cartilage. (B) Diagram of
collagen fiber architecture. From [2].

The superficial, or tangential, zone is the thinnest of all the layers and forms the
gliding surface of joints. This zone is composed of small diameter collagen fibers that
are densely packed and arranged parallel to the joint surface. The tangentially organized
collagen fibers provide the superficial zone the tensile and shear strength necessary to
withstand forces encountered on the joint surface. High collagen content, in addition to
low proteoglycan content and low permeability, makes the superficial zone the highest
water content zone. Chondrocytes of this region exhibit flattened, elongated shapes and
are also oriented parallel to the joint surface. These cells are coated by a thin layer of
lubricin that helps to provide a smooth gliding surface for joints and prevents wear and
tear from frictional forces.
The middle, or transitional, zone is thicker than the superficial zone making up
about 60% of the tissue’s total thickness.
6

The middle zone is composed of larger

diameter collagen fibers with a mesh-like, random orientation. Cell density in the middle
zone is lower than the superficial zone, and chondrocytes in the middle zone take on a
more spherical shape with orientations perpendicular to the joint surface. Proteoglycan
content is highest in this zone and in conjunction with the abundant ECM, makes the
middle zone ideal for withstanding compression.
The deep, or radial, zone is the last region of purely hyaline-tissue before reaching
bone. Collagen fibers in this zone form bundles aligned parallel to one another, but
oriented perpendicular to the joint surface. The cells of the deep zone become more
spheroidal in shape and begin to organize into columns orientated perpendicular to the
joint surface.
A fine borderline known as the “tidemark” separates the deep zone from the
calcified cartilage zone. The zone of calcified cartilage serves as a transitional zone
between the articular cartilage and the subchondral bone. Long collagen fibers from the
deep zone extend into the calcified zone and ultimately anchor into the subchondral bone,
providing fixation between the two tissues.
The ECM exhibits zonal organization as well as matrix organization dependent on
the distance from the chondrocyte cell membrane. These regions differ not only in
distance from the cells, but also in regard to biochemical composition and organization.
The region immediately surrounding the chondrocyte is the pericellular matrix, and is
characterized by fine collagen fibers and an abundance of proteoglycans. The territorial
matrix surrounds the cells and the pericellular matrix and provides protection from
mechanical impacts by surrounding the chondrocytes in a mesh of fine collagen fibers.
The region furthest away from the cell is termed the interterritorial matrix and comprises
the majority of articular cartilage. The proteoglycan content and collagen organization of
7

the interterritorial matrix are dependent on the distance from the joint surface, and
coincide with the zonal organization discussed previously.
Function
The primary function of articular cartilage is to provide a load bearing surface
with low friction and minimal wear. Articular cartilage allows for the transmission of
large loads between bones, while simultaneously allowing the smooth articulation
between the two bones. The ability of articular cartilage to withstand high cyclic and
intermittent loads over several decades with no signs of degeneration is a result of the
tissue’s unique biochemical and mechanical characteristics.
Since cartilage is essentially a porous, fluid-saturated matrix, it can be viewed as a
biphasic medium. The fluid phase is comprised of water and electrolytes, while ECM
components such as collagen and proteoglycans constitute the solid phase. Articular
cartilage can be characterized as a nonlinear, viscoelastic, anisotropic material.

In

solution, the negatively charged GAG chains of proteoglycans repel one another, causing
the aggrecan to distend and occupy a large volume. In the cartilage matrix, the aggrecan
is entangled within the collagen matrix, limiting the dispersion of the aggrecan.
Compression reduces spacing and increases the repulsive forces between the negatively
charged sites, adding to the compressive stiffness of the cartilage.

The mechanical

properties of articular cartilage are highly dependent on the fluid flow through the tissue.
Initial loading results in an immediate increase in interstitial pressure, causing fluid to
flow out of the ECM, and when the load is removed, fluid flows back into the tissue. As
fluid flows through the tissue, high drag forces are created due to articular cartilage’s low
permeability. This prevents fluid from quickly escaping the matrix, allowing the fluid
8

phase to support the majority of the load instead of the solid matrix. After a prolonged
period of loading, pressurization drops, fluid is no longer exuded from the tissue, and the
tissue reaches equilibrium. During this process, more and more of the force is transferred
to the solid fraction of the tissue until equilibrium is reached, at which point the solid
fraction supports the entire load. Certainly, the response of articular cartilage to load can
be attributed to the structure-function relationship between its components, but more
importantly relies on the interdependence between the tissue’s fluid flow and matrix
deformation.
Articular Cartilage Damage
Traumatic injury, repetitive loading, joint misalignment, and degenerative joint
disease can all damage articular cartilage, resulting in the reduced or complete loss of
tissue function. Unfortunately, once damaged, the natural healing response of articular
cartilage is unable to restore a fully functional tissue. Damage to articular cartilage can
be classified as either a chondral or an osteochondral defect. Chondral defects are those
that do not penetrate to the subchondral bone, whereas osteochondral defects penetrate
the subchondral bone, thereby gaining access to the bone’s vasculature.
In general, the body’s natural healing response involves three phases: necrosis,
inflammation, and repair [3].

Necrosis begins immediately after injury occurs and

involves cell death due to trauma. The inflammatory phase follows necrosis and is fully
dependent on the vascular system. Increased blood flow and vasodilatation results in the
formation of a dense fibrin network rich in inflammatory cells. The repair phase is
characterized by the creation of vascular granulation tissue and in some instances the
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formation of a scar. During the repair phase, the long process of remodeling begins in
order to restore identical tissue.
Chondral, or partial-thickness defects, are unable to heal spontaneously. Due to
the lack of vascularization within articular cartilage, the inflammatory and repair phases
of the healing response are unable to occur. Without a vascular system, phagocytic cells,
pluripotent cells, and growth factors are unable to be delivered to the area of trauma. In
addition, surrounding chondrocytes are unable to migrate to the injury site due to being
entrapped within the ECM.

The collagen network at the site of injury becomes

disrupted, resulting in GAG release, and thus weakening the tissue. Since no significant
healing takes place, these defects can result in osteochondral defects.
Osteochonral defects penetrate into the vasculature of subchonral bone and elicit
the more characteristic repair response. The repair process of full-thickness defects has
been extensively described by Shapiro et al. [4]. Disruption of the vasculature causes
blood to fill the defect, trapping red blood cells, white blood cells, and stem cells from
the marrow. The blood clot initially becomes a highly vascularized scar-like tissue, but
soon transforms into a fibrous cartilage-like tissue. Poor integration occurs between the
inferior fibrocartilage and the surrounding native tissue and areas of discontinuity are
frequently observed. The repair tissue lacks sufficient mechanical properties, becomes
fibrillated and begins to degenerate. The tissue’s poor functionality affects the
biomechanics of native tissue and alters the loading environment of the joint. Ultimately,
lesions that are left untreated will become progressively worse and lead to osteoarthritis.

10

Osteoarthritis
Osteoarthritis (OA) is the most common type of arthritis and is characterized by
the degeneration and eventual loss of cartilage in diarthroidal joints. Diagnosis of OA is
made radiographically and clinically. Radiographically, the loss of articular cartilage is
accompanied by changes in the underlying bone including development of marginal
outgrowths, osetophytes, and increased thinness of the bony envelop (bony sclerosis) [5].
Clinical symptoms are usually manifested in joint pain and reduced function. OA can
affect any diarthroidal joint, but is most commonly seen in the hands, hips, and knees.
Based on the severity, OA is graded on a scale from 1 to 4. In Grade 1 OA, the joint
space is preserved and OA is considered mild. Grade 4 is considered severe OA and is
characterized by the complete loss of articular cartilage resulting in bone-on-bone
articulation. OA is one of the leading disabilities of the developed countries and is
estimated to affect about 27 million people in the United States [6]. The prevalence of
OA increases with age and as the population ages, the socio-economic burden of OA will
become even greater [7].
Current Therapies
In order to repair damaged cartilage, the inherent deficiencies found in articular
cartilage must be overcome [8]. Most reparative methods have focused on introducing
new cells capable of chondrogensis and accessing the subchondral blood supply.
Although the natural repair response of articular cartilage results in the formation of
inferior fibrocartilage, many surgical therapies are based on this repair mechanism to
alleviate joint pain.

11

Debridement, Chondral Shaving, Lavage
Debridement and chondral shavings are procedures that are performed
arthroscopically to remove areas of damaged cartilage. Lavage, or simply rinsing of the
joint with a physiological fluid such as Ringers lactate, is usually carried out in
conjunction with debridement in order to remove degradation products from the joint.
These procedures do not repair or restore cartilage, but rather serve to temporarily relieve
pain and irritation. Since debridement, chondral shaving, or lavage are unable to restore
cartilage or alter disease progression, they are no longer recommended for treatment of
osteoarthritic knees [9].
Abrasion Arthroplasty, Subchondral Drilling, Microfracture
Abrasion arthroplasty, subchondral drilling, and microfracture are all reparative
strategies that are based on the penetration of subchondral bone in order to gain access to
the vasculature of the bone. The defect is then filled with bone marrow containing
pluripotent stem cells leading to blood clot formation and generation of fibrocartilage
repair tissue [10]. Microfracture has replaced the outdated abrasion arthroplasty and
subchondral drilling as the most popular one-stage arthroscopic procedure. Microfracture
involves the removal of damaged cartilage, forming a well-defined defect.
Microfractures are created using a specially bent awl which creates V-shaped perforation
holes 2 mm in diameter and 3 mm apart. Bleeding from the bone marrow is induced and
the blood clot adheres to the surface of the exposed bone, which begins the healing
process. Microfracture yields the best long-term results in young, active patients with
cartilage defects smaller than 2.5 cm2 [11].
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Figure 1.5

Different marrow stimulation techniques used for the treatment of cartilage
lesions and the associated tool of operation. (A) Typical femoral cartilage
lesion, (B) abrasion arthroplasty carried out by automated burr, (C)
microfracture carried out by bent awl, (D) subchondral drilling carried out
by automated driller. From [12].

Knee Replacement
When less invasive treatments are no longer an option, such as in end-stage OA,
total knee arthroplasty (TKA) may be a patient’s last option. Although TKAs do not alter
the progression of OA, the procedure does reduce pain and improve function. Total knee
replacements are performed if both the medial and lateral compartments must be
replaced.

If only the medial or lateral compartment must be replaced, then a

unicompartmental knee arthroplasty (UKA) can be performed.

Knee arthroplasty

involves the resurfacing of tibial and condylar surfaces by removing enough bone for the
placement of prosthetic components, which are commonly cemented to the bone [13].
13

Good fixation and restoration of the normal anatomical alignment are keys for a
successful knee arthroplasty.

The primary causes for failure or revisions of knee

arthroplasties are aseptic loosening, instability, and mal-alignment [14]. TKAs have
shown long-term success with some replacements lasting up to 20 years [15].
Tissue Grafts
The implantation of perichondrial and periosteal grafts has been explored as a
possible repair technique for osteochondral defects. Since periosteum is easier to obtain
and more abundant than perichondrium [16], periosteal grafts are more widely used.
Carranza-Bencan et al. demonstrated that resurfacing defects using perichondrial and
periosteal grafts produced superior results over the control group. The chondrogenic
potential of periosteum is derived from the chondrocyte precursor cells in the cambial
layer and has been demonstrated during fracture repair [17]. Implantation of periosteum
requires the creation of a full-thickness defect and removal of subchondral bone. The
tissue graft is then implanted into the defect with the cambial layer directed upward
towards the articular cartilage and fixed in place with fibrin glue [16]. In addition to the
periosteal chondrocyte precursor cells, mesenchymal stem cells from the marrow are also
introduced since debridement of the subchondral bone occurs. Although good results
have been reported with periosteal grafts, there is very limited clinical experience using
this technique. Therefore, further studies must be conducted in order to determine the
exact role of chondrocyte precursor cells in the repair response versus stem cells released
from the subchondral bone.
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Osteochondral Transfers
Osteochondral transfer is based on the transplantation of an entire osteochondral
unit, which includes the intact cartilage tissue and its underlying bone. Both autologous
and allogenic grafts have been widely used to repair medium and large osteochondral
defects. Autologous osteochondral transplantation, or mosaicplasty, involves harvesting
cylindrical osteochondral plugs from a non-weight bearing area of the joint for
transplantation to the defect area.

The osteochondral plugs for allogenic grafts are

harvested from organ donors instead of taking plugs from the recipient’s own joint. The
plugs are press fitted into the defect site and the areas between the plugs are filled by
fibrocartilage produced by the subchondral bone. Autologous grafts present no concerns
regarding an immunological response; however, a limited supply of autogenous tissue
and donor site morbidity are glaring issues. Furthermore, fitting the graft to match the
topology of the surrounding joint is a difficult task. On the other hand, allogenic grafts
can be harvested from the same location as the defective area, allowing for easy
restoration of the joint’s congruous surface. With allogenic grafts, donor age may vary so
the grafts can be harvested from younger patients. The major disadvantages of allogenic
grafts are the risks for an immune response and transmission of an infectious disease
from the donor.
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Figure 1.6

Schematic diagram illustrating steps involved in osteochondral transfer.
From [18].

Autologous Chondrocyte Implantation (ACI)
Autologous chondrocyte implantation involves arthroscopically harvesting a
healthy biopsy from a non-load bearing area of articular cartilage. The chondrocytes are
then isolated by enzymatic digestion and expanded in culture. After the chondrocytes are
expanded to a sufficient number, a second procedure is performed to debride the area and
a periosteal flap taken from the upper tibial surface is sutured over the defect. The
periosteal flap is sealed around the edges with fibrin glue and the autologous
chondrocytes are injected underneath the flap into the defect site. Results from ACI have
shown formation of hyaline-like repair tissue, as well as pain relief and restored joint
function in 80-90% of patients [19].

Studies have shown good results following
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treatment of osteochondral lesions, with durable results lasting up to 11 years [20].
However there are many disadvantages such as leakage of chondrocytes from the defect
site, uneven distribution of chondrocytes, and periosteal hypertrophy [21].

Further

investigation of the biochemical and mechanical nature the reparative tissue formed by
this technique is necessary to assure ACI’s superiority over existing treatments [8].

Figure 1.7

Schematic diagram showing the different stages involved in the process of
autologous chondrocyte implantation. From [18].

Each of the aforementioned treatments has shown limited success in
demonstrating long-term repair and all exhibit undesirable side effects. Most of the
success has been seen in small lesions with fibrocartilage being observed as the primary
repair tissue, which possesses inferior mechanical properties and often deteriorates over
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time. Tissue engineering is an evolving field that may serve as an alternate approach for
providing articular cartilage repair without the negative drawbacks of current therapies.
Tissue Engineering
Tissue engineering (TE) is a multidisciplinary field, which applies the principles
of engineering and the life sciences to develop tissues aimed at restoring, maintaining, or
improving tissue function [22]. Tissue engineering is comprised of the single use or
combination of scaffolds, cells, and signaling molecules. The goal of articular cartilage
tissue engineering is to generate tissue in vitro that is biochemically and mechanically
identical to native articular cartilage for implantation in vivo. Much focus has been given
to in vitro tissue engineering, because of the possibility of immediate functionality. The
ability to manipulate nutrient supply, cell signals, and mechanical stimuli to ensure the
tissue’s biochemical and biomechanical functionality is necessary before implantation
into the demanding environment of a joint.
Cell Source
Many cell sources have been investigated for tissue engineering articular cartilage
including chondrocytes (articular, auricular, and costal) and mesenchymal stem cells
(bone marrow and adipose). Chondrocytes seem to be the most logical choice since they
are found in native cartilage, produce ECM, and are already differentiated into the
desired phenotype. Although chondrocytes have been extensively used for cartilage
repair, these cells present two major concerns: lack of donor tissue and instability during
monolayer expansion. Harvesting chondrocytes via biopsies is limited by the amount of
donor tissue and usually yields low cell numbers, which require extensive expansion in
order to reach a suitable cell count.

Unfortunately, monolayer expansion of
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chondrocytes is associated with cell dedifferentiation, which is characterized by
decreased proteoglycan synthesis and type II collagen expression [23]. Recently, stem
cells have emerged as an alternative to autologous chondrocytes due to their availability
and high capacity of expansion. Stem cells are pluripotent cells that can potentially be
differentiated down various cell lineages under certain culture conditions. Sources for
adult mesenchymal stem cells include bone marrow and adipose tissue. Mesenchymal
stems cells are an intriguing cell source for tissue engineering cartilage, but the optimal
differentiation conditions and long term efficacy of these cells have yet to be fully
investigated.
Scaffolds
The scaffold provides a 3D environment and structure for the delivery of cells.
Ideally the scaffold should be porous with an interconnected network to permit cell
migration as well as nutrient and waste diffusion.

The scaffold should also be

biocompatible, biodegradable, and bioresorbable. Implantation of the scaffold must not
cause any immunogenic response, nor should the degradation products from the scaffold
yield any cytotoxic response. The time it takes for the scaffold to be replaced by ECM is
also an important factor. A balance must be found since slow degradation will hinder
new ECM production; whereas fast degradation may affect the structural stability of the
scaffold. The surface of the scaffold should also promote cell attachment, proliferation
and differentiation. This is usually done by enhancing the surface of the scaffold by
adding cell-adhesion promoting molecules to the culture media. Currently, there is no
particular scaffold that satisfies all of the numerous requirements, but the introduction of
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new polymer and natural-based scaffolds, along with the use of bioactive molecules
brings the creation of an ideal scaffold closer to reality.
Signaling Molecules
Cell signaling molecules bind to cells to create a biological response and include
growth factors, adhesion proteins, and peptide sequences. These bioactive molecules are
found throughout the body and are used in tissue engineering to induce, accelerate, and
enhance tissue formation.

The effect of various signaling molecules has been

investigated through in vitro tissue engineering, which has allowed us to define the
intensity, duration, and sequence of such molecules.
Several growth and differentiation factors concerning cartilage regulation have
been investigated, such as the Transforming Growth Factor Beta Family (TGF-β), Bone
Morphogenic Protein (BMPs), Cartilage Derived Morphogenic Protein (CDMP),
Fibroblast Growth Factors (FGFs), and Insulin-like Growth Factor-1 (IGF-1). TGF-β
isoforms are probably the most widely used growth factors with numerous studies
exploring the TGF-β family’s role in cartilage tissue engineering. TGF-β has been shown
to induce chondrogenesis in adult mesenchymal stem cells[24], increase ECM synthesis
[25], and enhance chondrocyte proliferation [26]. Growth factors are usually delivered as
soluble factors in growth media for in vitro purposes, but have also been incorporated
into scaffolds for timed-release after in vivo implantation. The surface of scaffolds can
be modified by protein coating and peptide incorporation in order to enhance cell
attachment and proliferation.
Although the role of growth factors has been shown to be very useful in cartilage
tissue engineering, much still remains unknown about these signaling molecules. The
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concentrations, dosage frequency, and affect of various cell sources must be further
investigated.

The long-term success of tissue engineering cartilage will depend on

identifying the combinatory results and optimal application of different growth factors.
Motivation, Rationale, and Specific Aims
In 1743, William Hunter stated, “From Hippocrates down to the present age, we
shall find, that an ulcerated cartilage is universally allowed to be a very troublesome
disease, and that when destroyed, it is never recovered” [27]. Over two and a half
centuries later, this statement still holds true today. When damaged, whether by trauma
or disease, articular cartilage lacks the intrinsic ability for self-repair. If left untreated,
injuries to cartilage can progressively become more severe and result in degenerative
osteoarthritis. The natural repair response that arises from the disruption of subchondral
bone results in the formation of fibrocartilage possessing inferior mechanical properties.
Current therapies for articular cartilage repair have demonstrated favorable short term
results, but are still unable to fully restore cartilage to its original state. Damage and
degeneration of articular cartilage presents a major health issue worldwide.

With

increasing joint injuries in adolescents and the aging population, the need for a superior
long-term treatment has become increasingly evident. The promise of tissue engineering
has led to the development of a wide range of reparative and regenerative strategies;
however, many challenges still remain.

Further investigation into cell source,

biomaterials, bioactive agents, and culture conditions are necessary in order to establish
an ideal method for articular cartilage repair.
The goals of this study are to: 1) tissue engineer sizeable, scaffold-free cartilage to
investigate the effect of Tissue Growth Technologies’ CartiGen Bioreactor on the tissue
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and 2) investigate chondrocyte and bone marrow-derived stem cell (BMSC) attachment
to chitosan.
Specific Aim 1) Tissue engineer sizeable, scaffold-free cartilage to investigate the
effect of Tissue Growth Technologies’ CartiGen Bioreactor on the TE cartilage.

Tissue

engineering has looked towards bioreactors as a means for producing a suitable
replacement tissue for cartilage. In this study, tissue engineered cartilage was created
from porcine chondrocytes with the goal of improving the biomechanical and
biochemical properties of the tissue through culture in the CartiGen bioreactor.
Specific Aim 2) Investigate chondrocyte and BMSC attachment to chitosan.
Chitosan possesses interesting properties such as nontoxicity, biodegradability, and
antimicrobial activity and has become a popular material for tissue engineering
applications. Chesnutt et al. have developed composite co-precipitated chitosan/nanocalcium phosphate (CaP) microsphere-based scaffolds which support osteoblast
attachment and growth, as well as overcome the limitations of mechanical strength and
interconnected porosity seen in previous scaffolds. We extend this work to investigate
the attachment of chondrocytes, BMSCs, and tissue engineered cartilage to chitosan/CaP
microsphere-based scaffolds.
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CHAPTER II
EFFECT OF A MECHANICAL STIMULATION BIOREACTOR ON SCAFFOLDFREE TISSUE ENGINEERED CARTILGE
Introduction
Tissue engineering has emerged as a promising approach to develop tissue with
identical properties to that of native articular cartilage. Generally, tissue engineering has
involved the incorporation of cells into a scaffold; however, there has been a recent move
towards a scaffold-free approach in order to avoid issues of biocompatibility, cell
attachment, porosity, rate of bioresorption, cytotoxicity of degradation products, and
stress-shielding [28]. Numerous approaches to forming scaffold-free constructs have
been described: pellet culture [29], active tissue contraction [30, 31], transwells [32-35],
custom molds [36-39], and agarose wells [40, 41]. Although scaffold-free engineered
cartilage grown in static culture reliably develops the main features of articular cartilage,
additional stimuli are required to increase the functional properties of the tissue. Two
candidate stimuli are perfusion and dynamic unconfined compression, each of which has
been shown independently to improve mechanical properties and enhance matrix
synthesis of tissue engineered cartilage [42-47]. For example, Bian et al. demonstrated a
significant increase in Young’s modulus for adult canine primary chondrocyte-agarose
constructs that were dynamically loaded in unconfined axial compression for three hours
a day compared to free-swelling controls [42]. A study by Davisson et al. revealed an
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increase in GAG synthesis and deposition by ovine articular chondrocyte constructs
seeded on PGA scaffolds over nine days of continuous perfusion [46].
The C9-x CartiGen bioreactor from Tissue Growth Technologies (Fig. 2.1) is a
means of simultaneously applying cyclic unconfined compression and perfusion to threedimensional cell cultures and may be useful for producing functional engineered
cartilage. The computer-controlled bioreactor system incorporates a motor, chamber, and
peristaltic pump. The single axis stimulator has a maximum displacement of + 5mm,
maximum sinusoidal force of + 20 N, and maximum frequency of 5 Hz. The chamber
holds nine samples in individual wells. Medium is pumped from a reservoir and enters
the bottom of each well through a porous metal disk. Having passed through and/or
around the sample, the perfused media empties into a central well and returns to the
reservoir. The objectives of this study were to: (i) describe the production of large, tissue
engineered cartilage using a novel scaffold-free approach and (ii) determine the effect of
perfusion and mechanical stimulation from the C9-x Cartigen bioreactor on the
mechanical and biochemical properties of the tissue engineered cartilage.
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Figure 2.1

CartiGen C9-x bioreactor from Tissue Growth Technologies. (A) Front
view showing chamber stand and single-axis stimulator. (B) Top view of
chamber showing nine wells with porous bottoms.
Methods

Cell Source
Articular cartilage was aseptically harvested from the femoral condyles and
femoral heads of 5 neonatal pigs.

The cartilage was pooled, minced, and digested

overnight in an incubator with 0.1% collagenase Type II in Dulbecco’s Modified Eagle
Medium (DMEM) containing 5% fetal bovine serum (FBS) and 1% antibiotic
antimycotic solution (100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 μg/ml
amphotericin B). After enzymatic isolation, the cell solution was filtered through a
100µm filter to separate isolated chondrocytes from undigested material and the
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chondrocytes were counted in a hemacytometer. Approximately 20 ml of a 2% molten
agarose solution in DMEM was poured into 50 ml polypropylene centrifuge tubes and
allowed to gel at 4°C. A suspension containing 6.5 x 107 cells was then added to each
tube and centrifuged at 2000g for 3 minutes to create compact cell layers about 1 mm
thick. The culture medium was initially high glucose DMEM containing 5% FBS, 1%
FGF, and 1% antibiotic antimycotic solution. After 24 hours, it was replaced with
defined chondrogenic medium:

high-glucose DMEM, 1% ITS+Premix (6.25 μg/ml

insulin, 6.25 μg/ml transferring, 6.25 μg/ml selenious acid, 1.25 mg/ml bovine serum
albumin, 5.35 μg/ml linoleic acid), 0.1 μM dexamethasone, 50 μg/ml ascorbate-2
phosphate, 1 mM sodium pyruvate, 40 μg/ml L-proline, 1% antibiotic antimycotic
solution, and 10 ng/ml of TGF-β3. The constructs remained in the tubes for 10 days with
defined chondrogenic medium, which was replaced every 3 or 4 days.

Static and Bioreactor Culture
After the 10-day consolidation phase the constructs were firm enough to handle
gently with forceps and cut with a scalpel. Each construct was removed from its tube and
an 8mm diameter disk was cored from the center using a biopsy punch. Six 8mm disks,
along with their concentric rings, were transferred to a six well plate, which had been
coated with a thin layer of agarose. These control constructs were incubated in defined
chondrogenic medium under static, free swelling conditions for the duration of the study.
The medium was changed twice a week. Nine disk-ring pairs were placed into each well
of the CartiGen chamber. They were positioned centrally within each well so that the
inner disk was coaxial with the 6 mm diameter smooth, impermeable loading head. The
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disks and concentric rings were subjected to constant surface perfusion with defined
chondrogenic medium at a flow rate of 0.5 mL/min for the duration of the four week
culture in the bioreactor. During the first week of culture in the CartiGen bioreactor, the
loading heads were stationed several millimeters above the disks and no mechanical
stimulation was applied. After the first week, disks were subjected to 1.0 Hz sinusoidal
unconfined compression under load control for four hours a day, five days a week,
beginning with a load of 0.5 N and increasing to 10 N and 20 N the second and third
weeks, respectively.

The loading heads were lifted several millimeters off of the

constructs during the rest periods. During loading, the total force applied to all nine
samples, as well as the displacement of the loading frame, were recorded for 10 seconds
at the beginning of the third hour of loading.

Dynamic compressive stiffness was

calculated as the peak-to-peak force divided by the peak-to-peak displacement.
Throughout the consolidation and bioreactor phases, the cultures were maintained in a
standard tissue culture incubator at 37°C and 5% CO2.
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Figure 2.2

GrowthWorks software user interface.

Figure 2.3

Gross appearance of static, perfused and loaded constructs. (A) static disk,
(B) static ring, (C) perfused ring, (D) loaded disk, and (E) loaded disk
thickness

Biomechanical Analysis
All biomechanical analyses were performed using the Biosyntech Mach-1 testing
system (Fig. 2.4). For unconfined compression tests, samples were transferred to a
stainless steel dish containing room temperature phosphate-buffered saline (PBS).
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Contact with each specimen was established by preloading to 10 g at 10 μm/s and
holding at this position until the force equilibrated. The unconfined compression test
consisted of four displacement ramps of 5% strain, each of which was followed by stress
relaxation to equilibrium. Force was normalized to sample cross-sectional area and the
equilibrium stresses were plotted against the applied strain. Equilibrium compressive
modulus was calculated as the slope of the best-fit line through these points. The stress
relaxation protocol was followed by a dynamic test, which consisted of a sinusoidal
profile with 3% strain amplitude at 0.01 Hz for 2 cycles, 0.025 Hz for 3 cycles, 0.25 Hz
for 10 cycles, and 1 Hz for 20 cycles. Using data from the cycles of each frequency, the
dynamic modulus was calculated as the peak-to-peak stress divided by peak-to-peak
strain.
Following the unconfined tests, samples were allowed to recover for at least 1
hour before undergoing confined compression testing. For the confined compression
tests, a 3.75 mm core of each sample was collected using a 3.75 mm punch. The disks
were placed into a custom polycarbonate holder consisting of a porous, stainless steel
base (Fig. 2.5) and were compressed with a solid stainless steel indenter. The confined
compression test consisted of one displacement ramp to 20% strain followed by stress
relaxation to equilibrium.

Aggregate modulus and hydraulic permeability were

determined by curve fitting the results to the linear biphasic theory of Mow et al. [48]
using the stress relaxation solution presented by Soltz and Ateshian [49].
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Figure 2.4

Biosyntech Mach-1micromechanical testing system. Configuration shown
is utilized for unconfined compression tests.

Figure 2.5

Custom polycarbonate well with porous bottom used for confined
compression tests.
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Biochemical Analysis
One-fourth of each disk was digested in 1% papain and 50 mM sodium acetate
(pH 6) at 60° C overnight. The total DNA content of the digestate was measured using
the Hoescht method (Sigma DNA-QF kit). Fluorescence intensity was measured using a
Vicam Series-4 Fluoremeter (Vicam, Milford, MA). Total GAG content from the same
digestate was quantified using the Blyscan Glycosaminoglycan Assay kit (Biocolor,
Newtonabby, Northern Ireland), based on dimethyl methylene blue binding.

The

remaining half of each disk, designated for collagen content, was incubated at 4° C for 48
hours in 0.05 M acetic acid containing 0.5 M NaCl (pH 3) and pepsin (10 mg/mL).
Pancreatic elastase (1 mg/mL dissolved in 1x TBS, pH 7.8-8.0) was added to the
digestate and mixed at 4° C overnight on a rotator rocker. Total collagen was determined
by the Sircol Assay (Biocolor) with absorbance at 540 nm measured using a BioTek
µQuant Microplate Spectrophotometer (BioTek Insturments, Winooski, VT).

Gross Morphology and Histology
Digital photographs were taken to record gross morphology and to measure the
diameter of each construct using Image J analyzing software (Image J 1.41, National
Institutes of Health, USA). Thickness for each construct was determined by finding
contact for each disk under a 10 g compressive load using the Mach-1 Micromechanical
testing system (Mach-1™ Motion, Bio Syntech Canada, Inc, Quebec, Canada).
One-fourth of each construct was fixed in 10% neutral buffered formalin,
embedded in paraffin, and sectioned (10 µm). Sections were stained with toluidine blue
to evaluate proteoglycan concentration.
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Results

.

Gross Morphology and Histology
Centrifugation (2000g, 3 min) onto agarose bottoms of 50 mL tubes compacted
cells into a relatively even layer about 1 mm thick covering the diameter of the tube.
After one week of static culture in the tubes, the constructs were firm and glossy, could
be cleanly cut by a biopsy punch (Fig. 2.6A), and could be easily handled and
manipulated with forceps (Fig. 2.6B). Although thickness increased in all groups from
the initial ~1 mm, there was no significant difference in thickness between the groups
after 5 weeks of culture (Fig. 2.7).
Histological evaluation shows an intense staining with toluidine blue in all
constructs, indicating an extracellular matrix rich in proteoglycans. However, higher
staining intensities of toluidine blue can be seen in the perfused and loaded groups
compared to the static group (Fig. 2.8).
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Figure 2.6

Gross appearance of tissue engineered, scaffold-free cartilage disks. (A)
Disk cut by 6 mm biopsy punch. (B) Torsion of disk with forceps
demonstrates ease of handling after 5 weeks culture.

Figure 2.7

Thickness of engineered, scaffold-free cartilage disks after 5 week culture
period.
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Figure 2.8

Histological sections of (A) static, (B) perfused, and (C) loaded constructs
stained with toluidine blue.
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Biochemical Analysis
All numerical results are expressed as the mean + SD. Total collagen content for
native porcine cartilage and the three experimental groups is shown in Figure 2.9.
Collagen content for the static (13.0902 + 4.4965), perfused (16.6458 + 6.8721), and
loaded (14.1936 + 3.6011) group was much lower than the native group (56.4460 +
13.9081). The amounts of collagen in the experimental groups were similar and did not
show any significant difference. Total GAG content for the experimental groups and
native porcine cartilage is shown in Figure 2.10. GAG content was much higher in the
perfused (79.4149 + 21.9862) and loaded (82.6923 + 18.4827) groups than the static
(47.3069 + 17.4817) and native (64.1732 + 5.3124) groups. Qualitative and quantitative
analysis of GAG content reveals a beneficial effect from culture in the bioreactor
compared to static culture. GAG content increased almost two fold in bioreactor cultured
constructs as opposed to statically cultured constructs. After five weeks of culture in the
bioreactor, the GAG/dw in the perfused and loaded groups exceeded that of native
porcine articular cartilage.
The DNA content was similar among the three experimental groups, but there was
no significant difference between static, perfused, or loaded groups (Fig. 2.11). The
DNA content was higher in the three experimental groups than in the native group but the
differences were not statistically significant.
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Figure 2.9

Total collagen content in engineered scaffold-free disks.
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Figure 2.10

Total GAG in engineered scaffold-free disks. (*) indicates significant
statistical difference vs. static (p < 0.001)
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Figure 2.11

Total DNA in engineered scaffold-free disks.

Biomechanical Analysis
During culture in the bioreactor, the compressive dynamic stiffness was
calculated for only the loaded constructs based on the recorded peak-to-peak force and
peak-to-peak displacement of the loading platens during periods of loading (Fig. 2.12).
The compressive dynamic stiffness of the loaded constructs not only increased each
week, but exhibited an increase in a linear fashion.
After removal from culture, all constructs underwent unconfined compression
tests to calculate dynamic modulus. Although both perfused (53.5394 + 33.7858 N/mm)
and loaded (17.9215 + 12.3923 N/mm) groups attained a higher dynamic modulus than
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the static group (5.2230 + 2.4777 N/mm), only the perfused group was significantly
higher (Fig. 2.13). However, both perfused and loaded groups had significantly higher
equilibrium compressive moduli than the static group (Fig. 2.14).
The equilibrium compressive modulus for the static group only reached 5.2943 +
2.7014 MPa, whereas the perfused group reached 67.1766 + 35.3546 MPa and the load
group reached 45.2495 + 16.6148 MPa. There was no significant difference in aggregate
modulus between the three groups (Fig. 2.15). The aggregate modulus for the loaded
group was only slightly higher than static, while the aggregate modulus of the perfused
group reached only about 50% that of the static group. Both perfused and loaded groups
attained a significantly lower hydraulic permeability than the static group (Fig. 2.16). The
hydraulic permeability for static (3.0993E10-14 + 1.7239E10-14

m4/Ns), perfused

(8.8478E10-15 + 4.2912E10-15 m4/Ns), and loaded (3.6447E10-15 + 1.6474E10-15 m4/Ns)
groups was lower than the hydraulic permeability previously found for neonatal articular
cartilage (12.7E10-14 m4/Ns ) [32]. The average percent stress relaxation of the static
group was 83.693 + 4.9157 %, while the average percent stress relaxation of the perfused
and loaded groups were significantly lower at 54.130 + 6.527 % and 62.288 + 8.059 %
respectively (Fig. 2.17). Both the perfused and loaded groups had stress relaxation
curves that were statistically different from the static group (Fig. 2.18).
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Figure 2.12

Dynamic stiffness of engineered scaffold-free cartilage calculated from
data obtained during loading in the CartiGen bioreactor.
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Figure 2.13

Dynamic modulus of engineered scaffold-free cartilage obtained from
unconfined compression tests.
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Figure 2.14

Equilibrium compressive modulus of engineered scaffold-free cartilage
determined from unconfined stress relaxation tests. (*) indicates
significant statistical difference vs. static (p < 0.001)
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Figure 2.15

Aggregate modulus of engineered scaffold-free cartilage determined by
curve fitting results from confined compression tests to the stress relaxation
solution of Soltz and Ateshian.
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Figure 2.16

Hydraulic permeability of engineered scaffold-free cartilage determined by
curve fitting results from confined compression tests to the stress relaxation
solution of Soltz and Ateshian. (*) indicates significant statistical
difference vs. static (p < 0.001).
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Figure 2.17

Percent stress relaxation of engineered scaffold-free cartilage. (*) indicates
significant statistical difference vs. static (p < 0.001).
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Figure 2.18

Stress relaxation properties of engineered scaffold-free cartilage. Note the
different mean stress relaxation curves of the three experimental groups.
Discussion

In this study, we introduce a novel method for producing sizable tissue engineered
cartilage from neonatal porcine chondrocytes utilizing a scaffold-free approach. We also
investigate the effects of culturing these tissue engineered constructs in a C9-x CartiGen
bioreactor from Tissue Growth Technologies. The nine constructs were mechanically
stimulated based on load control, which more closely mimics physiological conditions
more so than displacement control. The gross and histological appearances, biochemical
content, and mechanical properties of constructs cultured in a C9-x CartiGen bioreactor
were compared to constructs cultured statically and to native porcine cartilage. Our
results demonstrate that the CartiGen bioreactor is able to enhance both biochemical and
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mechanical properties of tissue engineered cartilage derived from neonatal porcine
chondrocytes.
The total DNA content was found to be similar among the static, perfused, and
loaded groups. Since total DNA content from bioreactor cultured constructs did not
differ from static cultured constructs, this suggests that the bioreactor did not promote or
enhance further cell proliferation over static culture conditions.
Although constructs cultured in the bioreactor achieved GAG levels higher than
native tissue, the constructs exhibited a deficiency in collagen. This high GAG content
along with low collagen content in tissue engineered cartilage has been reported by
numerous studies [50-52]. According to Riesle, the low collagen content could possibly
be attributed to enzymatic degradation as a result of fewer mature collagen cross-links in
tissue engineered cartilage [53]. In a comparative study between immature and mature
rabbit articular cartilage, Julkunen et al. determined that the collagen network does not
reach mature properties until around the age of three months [54]. After five weeks of
culture in the bioreactor, the collagen/dw in all groups reached about 33% that of native
porcine articular cartilage.
It has been well documented that glycosaminoglycans contribute to the
compressive properties of articular cartilage. The equilibrium compressive modulus of
bioreactor cultured groups was much higher than statically cultured groups and can be
attributed to the increase in GAG deposition in the perfused and loaded groups. The
higher GAG concentration in constructs cultured in the bioreactor is also reflected in the
lower permeability of those groups.

The lower permeability, in conjunction with

increased GAG content, resulted in a higher dynamic stiffness in perfused and loaded
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groups than in the static group. The permeability also directly affects the maximum peak
stress each construct can attain during the loading segment of stress-relaxation tests.
Therefore, a lower permeability allows the construct to support higher peak stresses. As
the results indicate, the perfused and loaded groups had significantly lower permeability
and significantly lower stress relaxations by percentage. Surprisingly, the aggregate
modulus for the perfused and loaded groups was not higher than the static group. The
average aggregate modulus for the loaded group was only slightly higher than static,
whereas the aggregate modulus of the perfused group reached only about 50% that of
static. This result may be due to the lack of collagen content in our tissue engineered
constructs. Earlier studies have shown the aggregate modulus to be dependent on GAG
content [55], but more recent studies have shown the aggregate modulus is also correlated
with collagen content [56, 57].

Mauck et al. observed that the aggregate modulus of

tissue engineered cartilage had an even stronger dependence on collagen content as
opposed to GAG content [57].
Our results clearly indicate an enhancement of properties in perfused and loaded
groups over the static group; however, there is no evidence from our study that suggests
the perfused or loaded condition produced a more superior tissue than the other. Both
mechanical stimulation and perfusion have been shown to improve the quality of tissue
engineered cartilage.

Dynamic compression stimulates chondrocyte metabolism and

increases matrix synthesis, thus improving the mechanical properties of tissue engineered
cartilage [44, 50, 57-61]. Perfusion has been linked to an accumulation of ECM in tissue
engineered cartilage by inducing shear stress on constructs and allowing for constant
nutrient supply and waste removal [46, 62, 63]. We expected to see an increase in
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biomechanical and biochemical properties from the perfused group compared to the
loaded group; however, there was no significant difference between the two groups. The
nine loading platens do not function independently from another, but rather all nine are
rigidly attached to a single, unidirectional stimulator. Therefore, it is difficult to ensure
that all constructs are receiving precisely the same load due to differences in thickness
between constructs. The majority of the load could possibly be borne by any number of
the constructs. Any additive effects related to mechanical stimulation may also have
been negated by direct contact from the impermeable loading platen which has been
shown to reduce synthesis of matrix products by disrupting nutritional transport to the
constructs [64].
In order to improve this method of tissue engineering, future studies should
involve the use of a more clinically relevant cell source such as adult chondrocytes or
bone-derived mesenchymal stem cells.

Utilizing a more mature cell source would

introduce additional variables such as age and cell passaging. Culture duration, initial
loading, and an optimized loading regime must also be further investigated in order to
produce tissue, which possesses sufficient properties for implantation.
Our study demonstrates that sizeable tissue engineered cartilage can be produced
from primary porcine chondrocytes using a scaffold-free centrifugation method.
Furthermore, the biomechanical and biochemical properties of these constructs are
enhanced via culture in a C9-x CartiGen bioreactor capable of applying mechanical
stimulation and constant perfusion. The ability to produce sizeable tissue engineered
cartilage possessing functional properties approaching that of native tissue serves as
progress towards future cartilage regeneration.
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CHAPTER III
INVESTIGATIONS INTO CHITOSAN FOR CARTILAGE TISSUE ENGINEERING
Introduction
Chitosan is a deacetylated derivative of chitin, which is the second most abundant
biopolymer behind cellulose. Chitin is found in the exoskeleton of marine crustaceans
and is produced by the seafood industry as industrial waste.

Chitosan is a linear

polysaccharide composed of glucosamine and N-acetyl glucosamine units linked by β(14) bonds. The ratio of glucosamine to N-acetyl glucosamine determines the degree of
deacetylation (DD) of the chitosan. Chitosan’s molecular weight can range from 50-1000
kDa and its DD can range from 50-90%, depending on the source and method of
preparation [31].

Chitosan has been a widely investigated biomaterial due to its

nontoxicity, biodegradability, enhancement of wound healing [65], antimicrobial activity
[66], and ability to be molded into various forms [67, 68]. Hydroxyapetite (HA) is one of
the major constituents of bone and has been widely used in orthopedic surgery due to its
biocompatibility and osteoconductivity [69, 70].
Chitosan and HA have been investigated as possible scaffold biomaterials for
tissue engineering cartilage and bone, respectively. When used alone, chitosan lacks the
mechanical properties required for load bearing activities, whereas HA is difficult to
shape due to its hardness and brittleness. A combination of both biomaterials could
provide an ideal scaffold for the repair of osteochondral defects, where both the articular
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cartilage and underlying bone are damaged. It has been shown that the incorporation of
HA into polymer matrices has increased the bone-binding capability of the polymer [71,
72].

Previous preparation methods have involved mixing HA powder in chitosan

solution [73] and coating a chitosan sheet with HA particles [74].

These methods

resulted in inhomogeneous composites with poorly integrated HA in the chitosan,
however co-precipitation methods have resulted in homogenous HA/chitosan composites
[67, 75, 76].
Chesnutt et al. developed composite co-precipitated chitosan/nano- calcium
phosphate (CaP) microsphere-based scaffolds which support osteoblast attachment and
growth, and overcome the limitations of mechanical strength and interconnected porosity
seen in previous scaffolds [77]. In this study, the work of Chesnutt et al. was extended to
investigate the attachment of tissue engineered cartilage to chitosan/CaP microspherebased scaffolds. The first objective was to investigate whether the formation of CaP
crystals on the chitosan was an immediate process that occurred after immersing the
chitosan in the precipitation solution or a gradual process that required soaking the
chitosan in the precipitation solution over a period of time. Next, a pilot study was done
to assess the chitosan’s ability to support the attachment of cells using porcine bone
marrow–derived mesenchymal stem cells (BMSCs). We followed with additional studies
to evaluate methods for creating a biphasic scaffold consisting of a layer of scaffold-free
cartilage attached to a porous chitosan scaffold using transwells and 15-mL centrifuge
tubes.
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Methods
Formation of Calcium Phosphate (CaP) Crystals
Chitosan Disc Fabrication
To prepare the chitosan solution, 3.57 g of 78.7% DDA chitosan powder (Vanson,
Remond, WA) was dissolved in 84 mL 2 wt% acetic acid. Ten mL of 1 M CaCl2 in 2%
acetic acid and 6 mL 1 M NaH2PO4 in 2% acetic acid was added to the chitosan solution.
The precipitation solution was composed of 20% NaOH, 30% methanol, and 50% water
(pH = 13). Enough precipitation solution was added to a 100 mL beaker to coat the
bottom and sides. Ten mL of chitosan solution was added to the beaker. Precipitation
solution was added via spray bottle to ensure the initial gelling of the top surface of the
chitosan. The chitosan discs were allowed to soak in the precipitation solution for either
10 minutes or 24 hours. After soaking, the chitosan discs were washed until a neutral pH
was reached.
For the control, 3.57 g of 78.7% DDA chitosan powder (Vanson, Remond, WA)
was dissolved in 100 mL of 2 wt% acetic acid. This chitosan solution did not include
CaCl2 and NaH2PO4, therefore preventing formation of any calcium phosphate crystals.
Once again, enough precipitation solution was added to a 100 mL beaker to coat the
bottom and sides. Ten mL of the control chitosan solution was added to the beaker.
Precipitation solution was added via spray bottle to ensure the initial gelling of the top
surface of the chitosan. The chitosan discs were allowed to soak in the precipitation
solution for 24 hours. After soaking, the chitosan discs were washed until a neutral pH
was reached as described previously.
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Transmission Electron Microscopy
Samples of control chitosan, chitosan soaked for 10 minutes, and chitosan soaked
for 24 hours were trimmed and faced for cutting by an ultra-microtome (Reichert Junt
Ultracut E). Thin sections (75 nm) were cut and then collected on a copper grid. The
sections were viewed with a JEOL JEM-100CXII TEM scope at 60-80kV.

BMSC Attachment to Microspheres
Chitosan Microsphere Fabrication
Chitosan solution was prepared as described previously. The chitosan solution
was placed in a 30-mL syringe fitted with a 21-g needle. The syringe was placed in a
syringe pump and dripped into a precipitation solution with constant stirring. An air line
was attached to the syringe to force the chitosan solution off of the tip of the needle. The
size of the chitosan microspheres could be fabricated to a desired size by controlling the
air flow. The chitosan solution immediately formed into solid beads after being dripped
into the precipitation solution. The microspheres were left in the precipitation solution
for 24 h to allow crystalline CaP to develop. The microspheres were then washed in
numerous changes of deionized water until they reached a neutral pH (7.0-7.5). The pH
was measured with a pH meter after each change of DI water.
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Figure 3.1

Setup for chitosan microsphere formation. Chitosan solution was dripped
from the needle by a syringe pump. Air line was attached to the syringe to
control the size of the microspheres based on air flow.
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Figure 3.2

Image of various sizes of microspheres taken by a dissection microscope.
Cell Source and Culture

Bone marrow derived mesenchymal stem cells (BMSCs) were obtained from the
femur and tibia of neonatal pigs. Working under aseptic conditions, the femurs and tibias
were removed and cleaned of any connective tissue. Bones were briefly rinsed in 10%
bleach, washed in 70% ethanol, and then allowed to dry in a sterile Pyrex dish on ice.
The bones were cut in half and each half was placed in a syringe with the open end of the
bone pointed downward. Each syringe was placed in a 50 ml centrifuge tube and then
centrifuged for 10 minutes at 200 g to extract the marrow from the bone. Centrifugation
causes the bone marrow to pass through the syringe and collect in the bottom of the 50
mL centrifuge tube. Syringes and bones were removed and bone marrow was pooled.
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The bone marrow was then pipetted into culture flasks and allowed to incubate overnight.
Since BMSCs are substrate dependent, they adhere to the flasks. Rinsing the flasks the
following day will remove the non-adherent blood cells, leaving a population of BMSCs.
The porcine BMSCs were detached using 0.25% trypsin-EDTA and recovered from the
flasks.

A cell suspension containing 500,000 BMSCs was added to a sterile

microcentrifuge tube containing two or three chitosan microspheres and allowed to attach
for 24 hours in a standard tissue culture incubator at 37°C and 5% CO2.

Scanning Electron Microscopy
Samples were fixed in 2.5% glutaraldehyde, dehydrated in a graded ethanol
series, and chemically dried with Hexamethyldisilazane (HMDS). After drying, samples
were placed with desiccant until mounting. Samples were mounted to stubs using carbon
tape and sputter coated with gold-palladium. The samples were viewed with a JEOL
JSM-6500F at 5 kV. The surface of the chitosan microspheres were examined visually
for cell attachment and images were recorded. Unseeded chitosan was also imaged to
examine surface topography and to serve as a control for comparison.

Biphasic Constructs (Transwell Model)
Scaffold Fabrication
Chitosan microspheres were created as described earlier. The microspheres were
then packed into 6.5 mm diameter transwells and fused into cylindrical plugs by washing
with 1% acetic acid for 20 seconds and placed in deionized water for rinsing. The
cylindrical scaffolds were removed from the deionized water and allowed to dry for 24 h.
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Dry scaffolds were sterilized by ethylene oxide. Before cell seeding, scaffolds were
rehydrated in medium containing 5% fetal bovine serum (FBS) and 1% antibiotic
antimycotic solution (100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 μg/ml
amphotericin B) for 24 hours to coat the scaffolds with cell-essential proteins and
facilitate cell attachment.

Cell Source and Culture
Articular cartilage was aseptically harvested from the femoral condyles and
femoral heads of neonatal pigs.

The cartilage was pooled, minced, and digested

overnight in an incubator with 0.1% collagenase Type II in Dulbecco’s Modified Eagle
Medium (DMEM) containing 5% fetal bovine serum (FBS) and 1% antibiotic
antimycotic solution (100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 μg/ml
amphotericin B). After enzymatic isolation, the cell solution was filtered through a
100µm filter to separate isolated chondrocytes from undigested material.

The

chondrocytes were seeded into two Corning Hyperflasks and cultured till near
confluence. The chondrocytes were detached from the hyperflasks using 0.25% trypsinEDTA.
To create the bilayered constructs, 10 million chondrocytes were seeded into a
Millicell hanging transwell for 24-well plates (6.5 mm diameter, 3.0 μm PET membrane)
and allowed to settle. The wells of the 24-well plate were filled with half complete
medium containing 5% fetal bovine serum (FBS) and 1% antibiotic antimycotic solution
(100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 μg/ml amphotericin B) and half
defined chondrogenic medium containing 1% ITS+Premix (6.25 μg/ml insulin, 6.25
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μg/ml transferring, 6.25 μg/ml selenious acid, 1.25 mg/ml bovine serum albumin, 5.35
μg/ml linoleic acid), 0.1 μM dexamethasone, 50 μg/ml ascorbate-2 phosphate, 1 mM
sodium pyruvate, 40 μg/ml L-proline, 1% antibiotic antimycotic solution, and 10 ng/ml
of TGF-β3. Following the initial culture in half complete medium and half defined
chondrogenic medium, the constructs were cultured in defined chondrogenic medium
which was replaced every three or four days. After two weeks of culture, an additional
10 million chondrocytes were added to each insert, along with a chitosan scaffold. The
constructs were cultured for another six weeks to allow for maturation and integration.
Porcine BMSCs were obtained as described earlier. The BMSCs were seeded
into two T-175 flasks and then split into nine T-175 flasks after the flasks reached near
confluence. The BMSCs were detached from the nine T-175 flasks using 0.25% trypsinEDTA.

The BMSCs were used to create bilayered constructs following the same

protocol as described previously involving chondrocytes.

Scanning Electron Microscopy
The chitosan scaffolds and the scaffold-free cartilage were fixed in 2.5%
glutaraldehyde, dehydrated in a graded ethanol series, and chemically dried with
Hexamethyldisilazane (HMDS). Samples were mounted to stubs using carbon tape and
sputter coated with gold-palladium. The samples were viewed with a JEOL JSM-6500F
at 5 kV. Images of the scaffold-free cartilage’s surface were acquired, along with images
of the surface and pores of the chitosan scaffold.
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Biphasic Constructs (15-mL Centrifuge Tube)
Cell Source and Culture
Porcine articular chondrocytes were obtained, expanded, and harvested as
described earlier. Approximately 2 ml of a 2% molten agarose solution in DMEM was
poured into 15 ml polypropylene centrifuge tubes and allowed to gel at 4°C.

A

suspension containing 5 million cells was then added to each tube and centrifuged at
1000g for 3 minutes to create a thin, compacted cell layer. Chitosan scaffolds, formed in
transwells as described earlier, were placed into the 15 mL tubes and centrifuged at 200g
in order to embed the scaffolds into the cell layer. Initally, the 15 mL tubes were filled
with 5 mL complete medium containing 5% fetal bovine serum (FBS) and 1% antibiotic
antimycotic solution (100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.25 μg/ml
amphotericin B) and 5 mL defined chondrogenic medium. The constructs were
replenished with defined chondrogenic medium about once a week.

The biphasic

constructs were maintained in a standard tissue culture incubator at 37°C and 5% CO2 for
the entire study. After six weeks, constructs were fixed in 10 % neutral buffered formalin
for three hours and then transferred to 70% ethanol.

Histology

.

The fixed constructs were sent to the University of Alabama-Birmingham’s
Center for Metabolic Bone Disease core laboratory for processing. The constructs were
embedded in paraffin and sectioned for staining with Hemotoxyline and Eosin (H&E),
Toluidine Blue, and Safranin-O.
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Results

.

CaP Formation
Samples were examined by TEM for qualitative assessment of crystalline CaP
formation.

TEM micrographs of the control chitosan prepared without CaCl2 and

NaH2PO4 reveal that CaP crystals did not form on the chitosan after 24 hours in
precipitation solution.

Figure 3.3

10,000X TEM micrograph of chitosan without calcium phosphate after 24
hours in precipitation solution.

TEM micrographs of the chitosan prepared with CaCl2 and NaH2PO4 reveal CaP crystals
dispersed throughout the chitosan for the 10 minute and 24 hour samples (Fig. 3.4).
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Figure 3.4

(A) 10,000X TEM micrograph of chitosan with calcium phosphate after 10
minutes in precipitation solution. (B) 10,000X TEM micrograph of
chitosan with calcium phosphate after 24 hours in precipitation solution.
(C) 50,000X TEM micrograph of chitosan with calcium phosphate after 10
minutes in precipitation solution. (D) 50,000X TEM micrograph of
chitosan with calcium phosphate after 24 hours in precipitation solution.
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BMSC Attachment to Microspheres
The BMSCs seemed to attach and encase the chitosan microspheres upon initial
gross examination after 24 hours of culture.

Samples were examined by SEM for

qualitative assessment of cell attachment. Figure 3.5 shows the surface morphology of
the control chitosan microsphere. The rough and textured morphology of the chitosan
microsphere is presumably beneficial for cell attachment and growth due to the increased
surface area. The uneven surface topology results in many depressions and cavities that
could enhance the strength of the cell-chitosan interface.

Figure 3.5

30,000X SEM micrograph of a chitosan microsphere’s surface
morphology.
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Figure 3.6, an image taken at low magnification, shows the majority of a chitosan
microsphere encased by cellular material. In some areas, the layer of tissue appears to
contact and attach to the microsphere, whereas in other areas the tissue appears to form
an encasement around the microsphere rather than directly attaching to the chitosan.

Figure 3.6

120X SEM micrograph of a chitosan microsphere encased by porcine
BMSCs.

63

At higher magnification, the BMSCs seem to adhere to the chitosan fairly well
(Fig. 3.7). Further magnification shows what seems to be a layer of extracellular material
covering the surface of the chitosan microsphere (Fig. 3.8).

Figure 3.7

350X SEM micrograph of porcine BMSCs attached to the surface of a
chitosan microsphere.
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Figure 3.8

2700X SEM micrograph of ECM from porcine BMSCs covering the
surface of a chitosan microsphere.

Biphasic Scaffold (Transwell)
The goal was to create a biphasic construct consisting of a layer of scaffold-free
tissue engineered cartilage affixed to a scaffold comprised of fused chitosan
microspheres. Gross examination revealed that the chondrocytes were able to consolidate
into a layer of scaffold-free tissue engineered cartilage in the transwell; however, the
layer of tissue engineered cartilage did not integrate into the chitosan scaffold. Extraction
from the transwell yielded two completely separate entities with the layer of cartilage
shearing off of the scaffold with relative ease.
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Figure 3.9

(A) Bilayered construct consisting of an upper layer of scaffold-free
cartilage supported underneath by a chitosan scaffold composed of fused
microspheres. (B) Top and (C) side view of the separated bilayered
construct.
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SEM images of scaffold-free cartilage revealed a flat, smooth surface with
circular chondrocytes and large amounts of ECM (Fig. 3.10). Further magnification
showed chondrocytes embedded and surrounded by a dense ECM (Fig. 3.11).

Figure 3.10

200X SEM micrograph of the surface of scaffold-free tissue engineered
cartilage formed from porcine chondrocytes.
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Figure 3.11

3300X SEM micrograph scaffold-free tissue engineered cartilage formed
from porcine chondrocytes.

Examination of the chitosan scaffold by SEM showed chondrocytes had begun to
fill the pores and bridge gaps between microspheres with ECM (Fig. 3.12) and that cells
had firmly adhered to the surfaces of the microspheres and maintained a rounded
morphology (Fig. 3.13).
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Figure 3.12

85X SEM micrograph of porcine chondrocytes attached to fused chitosan
microspheres.
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Figure 3.13

5,000X SEM micrograph of a porcine chondrocyte attached to the surface
of a fused chitosan microsphere.
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Examination of chitosan scaffolds seeded with BMSCs showed cells readily
attached to the surface of the scaffold and beginning to fill in spaces between
microspheres (Fig. 3.14). The BMSCs also had a rounded morphology characteristic of
chondrogenic differentiation (Fig. 3.15).

Figure 3.14

70X SEM micrograph of porcine BMSCs attached to fused chitosan
microspheres.
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Figure 3.15

3,000X SEM micrograph of porcine BMSCs attached to the surface of a
fused chitosan microsphere.

Biphasic Construct (15-mL Centrifuge Tube)
The second effort to create a biphasic construct involved centrifuging a
chondrocyte cell suspension in 15 mL tubes with agarose bottoms. Removal of the
construct from the 15 mL tube after six weeks of culture revealed that the layer of
cartilage was not affixed to the chitosan scaffold. The cartilage adhered around the
exterior forming a ring around the scaffold (Fig. 3.16). Hemotoxylin and Eosin (H&E)
stained sections showed that the tissue was not only attached to the exterior of the
scaffold but also infiltrated into the scaffold between the microspheres (Fig. 3.17).
Figure 3.18 shows the tissue encompassing an entire microsphere. Sections were also
stained with Toluidine Blue and Safranin-O for proteoglycan assessment, both of which
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display intense staining which is indicative of a matrix rich in proteoglycans (Fig. 3.19,
3.20).

Figure 3.16

Gross appearance of a biphasic construct formed in 15-mL centrifuge
tubes.
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Figure 3.17

10X H&E section of a bilayered construct showing cartilage growth around
and between chitosan microspheres.
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Figure 3.18

10X H&E section of a bilayered construct showing cartilage encompassing
an entire chitosan microsphere.
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Figure 3.19

10X toluidine blue section of scaffold-free cartilage around a chitosan
microsphere.
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Figure 3.20

10X safranin-O section of scaffold-free cartilage cultured on a chitosan
scaffold.
Discussion

Chitosan has been regarded as one of the most promising biopolymers for bone
and tissue engineering.

Chesnutt et al. have designed and characterized a novel

chitosan/nanocrystalline calcium phosphate composite scaffold for bone regeneration.
This work extends that study to investigate the potential application of chitosan in tissue
engineering cartilage.
We have demonstrated the ability to form chitosan into defined geometries such
as disks and various sized microspheres. Our microsphere fabrication method, which
involves an air line attached to a syringe pump, allows for the formation of various sized
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microspheres based on the rate of air flow. The microspheres can in turn be packed into
molds of various shapes and fused with acetic acid to from three dimensional porous
structures. The porosity of the three dimensional construct can be adjusted based on the
size of the microspheres.
This study investigating CaP crystal formation on chitosan showed that the
process occurred almost instantaneously. Qualitative assessment by SEM showed little
difference between chitosan soaked in precipitation solution for 10 minutes and chitosan
soaked in precipitation solution for 24 hours. Since CaP crystalline formation is not a
time dependent process, the chitosan needs only to remain in the precipitation solution
until it solidifies.
The initial investigation involving cell attachment to chitosan demonstrated that
the chitosan was able to support the attachment of BMSCs. BMSCs not only attached to
the chitosan, but also were found to produce ECM covering areas of the chitosan surface.
Confirming cell attachment to chitosan microspheres was necessary in moving toward
creating bilayered constructs.
For the creation of a bilayered construct, the transwells were utilized as a mold to
fuse together the chitosan microspheres to create scaffolds and to confine the
chondrocytes, thus resulting in a scaffold and cell layer with a circular geometry and
equivalent diameters. Transwell inserts have previously been used to successfully create
tissue engineered, scaffold-free cartilage with a defined geometry and smooth surface
[32, 78]. Ideally, this method would yield a bilayered construct consisting of tissue
engineered cartilage integrated with a porous chitosan scaffold. Unfortunately, the tissue
engineered cartilage failed to integrate with the chitosan scaffold. Two cell sources,
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porcine chondrocytes and porcine BMSCs, were used and neither resulted in a strong
attachment between the cartilage and scaffold. Poor adhesion and integration between
the cartilage layer and scaffold could be due to the second cell seeding not efficiently
attaching to the previously formed cartilage as a result of poor diffusion and nutrient
supply. Most likely, the reduced efficacy of the cells to integrate the cartilage layer and
scaffold is a result of the cells being constrained between the layer of cartilage and the
chitosan scaffold. Nutrient supply and diffusion to the cells through the transwell’s PET
membrane may have been prevented by the layer of cartilage and any exchange between
the bulk media and media within the transwell may have been hindered by the chitosan
scaffold. Failure of the cartilage layer to integrate with the scaffold may also be due to
insufficient pore diameter. Small pores limit the degree to which the tissue can penetrate
the scaffold. Increasing the diameter of the microspheres will lead to larger pore sizes
and possibly improve tissue integration into the scaffold.
Our creation of a bilayered scaffold using 15-mL centrifuge tubes differed from
the transwell method in a couple of ways. First, the chondrocytes were centrifuged to
create a cell layer instead of being allowed to settle and consolidate on their own.
Centrifugation of chondrocytes has been shown to increase proteoglycan synthesis [79],
which could improve the attachment process between the cartilage layer and scaffold.
Also, instead of merely placing the scaffold on the cell layer, the scaffold was added and
then spun at 200g to embed the scaffold in the cell layer. Although the creation of a
bilayered scaffold was unsuccessful, we were able to show tissue attachment to the
chitosan scaffold as opposed to only cell attachment as seen in the past. Histological
evaluations confirm that the cartilage was indeed attached to the chitosan scaffold. The
79

space seen between the tissue and chitosan can be attributed to histological processing
and shrinkage of the chitosan.
This study extended the work of Chesnutt et al. involving novel chitosan/
nanocrystalline calcium phosphate composite scaffolds for bone regeneration to cartilage
tissue engineering. Chesnutt has already shown the composite scaffolds are able to
support osteoblast attachment and proliferation.

Our results have demonstrated the

scaffold’s ability to also support chondrocyte and BMSC cell attachment, thus making
the scaffold a possible candidate for producing biphasic constructs for osteochondral
repair. In the future, it will be necessary to assess cell attachment quantitatively by
measuring DNA or utilizing a MTS assay. Culture conditions and duration will need to
be optimized in order to ensure the strong attachment of the cartilage layer to the chitosan
scaffold. Much more research will be required in order to create a bilayered construct
consisting of a layer of tissue engineered cartilage attached to a porous chitosan scaffold;
however, we have demonstrated the potential of novel chitosan/nanocrystalline calcium
phosphate composite scaffolds for osteochondral repair.
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CHAPTER IV
SUMMARY
The two main goals of this dissertation were to investigate the effect of Tissue
Growth Technologies’ CartiGen Bioreactor on scaffold-free tissue engineered cartilage
and to explore the potential use of composite chitosan/CaP scaffolds for tissue
engineering biphasic scaffolds for osteochondral defects.

In the first study, a novel

method for producing sizable tissue engineered cartilage from neonatal porcine
chondrocytes utilizing a scaffold-free approach was demonstrated. Conditioning of the
cartilage in Tissue Growth Technologies’ CartiGen bioreactor resulted in an enhancement
of the cartilage’s biochemical and biomechanical properties.
In the second study, the ability of novel chitosan/nanocrystalline calcium
phosphate composite scaffolds to support the attachment of porcine chondrocytes and
BMSCs and the integration of tissue engineered cartilage with a chitosan scaffold was
investigated. The study demonstrated the successful attachment of both chondrocytes
and BMSCs to the chitosan microspheres.

Successful attachment studies warranted

further attempts to produce bilayered constructs consisting of a layer of tissue engineered
cartilage attached to a chitosan scaffold composed of fused microspheres. Although
bilayered constructs demonstrated poor integration between the tissue layer and scaffold,
the potential for these chitosan microspheres in osteochondral repair is evident.
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Fetal Pig BMSC Isolation
Materials
Autoclave beakers, Pyrex dish, PBS, drape
Syringe
50 ml tubes
10% bleach
70% ethanol
Method
Remove femurs or tibias using aseptic technique
Remove all connective tissue from bones
Keep bones on ice
Rinse briefly in 10% bleach
Wash in 70% ethanol
Allow to dry in Pyrex dish on ice
Break bones in half using sterile wire cutters and place in syringe, broken side down
Place syringe in 50 ml tube and centrifuge at 200g for 10 minutes
Remove syringes and pool marrow for seeding into flasks
SEM Fixation
Samples fixed in 2.5% Glutaraldehyde
1-2 hrs
Dehydrated in series of ethanol:
70%
1 hr
80%
1 hr
90%
1 hr
100%
1 hr
100%
overnight
50% EtOH – 50% HMDS
4-6 hrs
100% HMDS
overnight
Remove HMDS and allow to air dry. Store with desiccant until sputter coating.
Papain Digestion
Prepare immediately before use:
Add 1 mg cysteine per mL of 50 mM Sodium Acetate (pH to 6 with acetic acid)
[weigh cysteine first]
Add 10 μl papain per mL of Sodium Acetate/cysteine
Warm water bath to 37 °C
Digest scaffold in 1 ml at 60 °C overnight
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Blyscan Sulfated Glycosaminoglycan Assay
Set up assay:
Label a set of 1.5 ml microcentrifuge tubes. If sufficient material is available, run
duplicate samples.
Prepare:
[1] Reagent blanks, (100 μl of distilled water
or the test sample buffer).
[2] Glycosaminoglycan standards,
(aliquots containing 1.0, 2.0, 3.0, 4.0 & 5.0 μg).
[3] Test samples, (volumes: 10 to 100 μl).
Adjust the contents of all tubes to 100 μl with
distilled water or appropriate buffer.
To each tube add 1 ml Blyscan dye reagent and cap all of the tubes.
Mixing:
Place tubes on a mechanical shaker for 30 minutes, (or manually shake at 5 minute
intervals). During this time period the Blyscan dye will bind to sulfated
glycosaminoglycans. The dye reagent is designed so that the sGAG-dye complex will
precipitate out of solution.
Centrifuging:
Transfer the tubes to a micro centrifuge and spin the tubes at > 10,000 x g for 10 minutes.
It is important to firmly pack the insoluble pellet of the sGAG-dye complex at the bottom
of the tubes, so as to avoid any loss during draining.
Draining:
The unbound dye solution is removed by carefully inverting and draining the tubes. Any
remaining droplets can be removed from the tubes by gently tapping the inverted tube on
a paper tissue. Do not attempt to physically remove any fluid that is in close contact to
the deposit.
Release of bound dye:
To each tube add 1 ml of the dissociation reagent. Re-cap the tubes and release the
bound dye into solution. A vortex mixer is suitable. When the bound dye has been
dissolved, usually within 10 minutes, the samples are ready for measurement. The color
is light stable, but should be read within 2 hours. Keep the tubes capped until ready for
measurement.
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Measurement:
Multiwell plate reader, set to read at 450 nm. Transfer 200 μl aliquots of samples from
tubes to the wells of a 96 well, multiwell plate. Measure absorbance of reagent blanks
glycosaminoglycan standards and the test samples. Subtract the reagent blank reading
from the standard and test sample readings.
Sircol Collagen Assay
Set Up Assay:
Label a set of 1.5ml microcentrifuge tubes. If sufficient test material is available run
duplicate samples.
Prepare:
Reagent blanks - 100μl of deionised water or 0.5M acetic
acid or fresh cell culture medium or extraction buffer.
Collagen standards - use aliquots containing 5, 10, 25, and 50 μg of the Collagen
Reference Standard. Make each standard up to 100μl using the same solvent as the
reagent blanks.
Test samples - use volumes between 10 and 100μl. Adjust the contents of all tubes to 100
μl with distilled water or appropriate buffer.
To each tube add 1 mL sircol Dye reagent and cap all of the tubes; mix contents by
inverting.
Mixing:
Place tubes in a gentle mechanical shaker for 30 minutes, (or manually mix at 5 minute
intervals). During this time period a collagen-dye complex will form and precipitate out
from the soluble unbound dye.
Centrifuging:
Transfer the tubes to a microcentrifuge and spin at >10,000 r.p.m. for 10 minutes. It is
important to firmly pack the insoluble pellet of the collagen-dye complex at the bottom of
the tubes, as to avoid any pellet loss during draining of unbound dye.
Draining:
The unbound dye solution is removed by carefully inverting and draining the tubes. Any
remaining droplets can be removed from the tubes by gently tapping the inverted tube on
a paper tissue. Do not attempt to physically remove any fluid that is in close contact to
the deposit.
91

Release of bound dye:
To each tube add 1 mL of the Alkali reagent. Recap tubes and release the collagen bound
dye into solution. A vortex mixer is suitable. When all of the bound dye has been
dissolved, usually within 10 minutes, the samples are ready for measurement. The color
is light stable, but should be read within 2 to 3 hours. Keep tubes capped until ready for
measurement.
Measurement:
Multiwell plate reader, set to read at 540 nm. Transfer 200 μl aliquots of samples from
tubes to the wells of a 96 well, multiwell plate. Measure absorbance of reagent blanks,
collagen standards and the test samples. Subtract the reagent blank reading from the
standard and test sample readings.

92

